7T01
SARS-CoV-2 S-RBD + Fab 54042-4
Summary for 7T01
Entry DOI | 10.2210/pdb7t01/pdb |
EMDB information | 25574 |
Descriptor | Spike protein S1, 54042-4 Fab - Heavy Chain, 54042-4 Fab - Light Chain (3 entities in total) |
Functional Keywords | sars-cov-2, 54042-4, rbd, fab, complex, viral protein-immune system, viral protein |
Biological source | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2) More |
Total number of polymer chains | 3 |
Total formula weight | 47483.42 |
Authors | Johnson, N.V.,Mclellan, J.S. (deposition date: 2021-11-29, release date: 2022-04-13, Last modification date: 2024-11-13) |
Primary citation | Kramer, K.J.,Johnson, N.V.,Shiakolas, A.R.,Suryadevara, N.,Periasamy, S.,Raju, N.,Williams, J.K.,Wrapp, D.,Zost, S.J.,Walker, L.M.,Wall, S.C.,Holt, C.M.,Hsieh, C.L.,Sutton, R.E.,Paulo, A.,Nargi, R.S.,Davidson, E.,Doranz, B.J.,Crowe Jr., J.E.,Bukreyev, A.,Carnahan, R.H.,McLellan, J.S.,Georgiev, I.S. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Rep, 37:109784-109784, 2021 Cited by PubMed Abstract: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages that are more transmissible and resistant to currently approved antibody therapies poses a considerable challenge to the clinical treatment of coronavirus disease (COVID-19). Therefore, the need for ongoing discovery efforts to identify broadly reactive monoclonal antibodies to SARS-CoV-2 is of utmost importance. Here, we report a panel of SARS-CoV-2 antibodies isolated using the linking B cell receptor to antigen specificity through sequencing (LIBRA-seq) technology from an individual who recovered from COVID-19. Of these antibodies, 54042-4 shows potent neutralization against authentic SARS-CoV-2 viruses, including variants of concern (VOCs). A cryoelectron microscopy (cryo-EM) structure of 54042-4 in complex with the SARS-CoV-2 spike reveals an epitope composed of residues that are highly conserved in currently circulating SARS-CoV-2 lineages. Further, 54042-4 possesses uncommon genetic and structural characteristics that distinguish it from other potently neutralizing SARS-CoV-2 antibodies. Together, these findings provide motivation for the development of 54042-4 as a lead candidate to counteract current and future SARS-CoV-2 VOCs. PubMed: 34592170DOI: 10.1016/j.celrep.2021.109784 PDB entries with the same primary citation |
Experimental method | ELECTRON MICROSCOPY (2.69 Å) |
Structure validation
Download full validation report
